ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Tarceva Reaches Endpoint Early: Longer PFS Than Chemo Alone

February 25, 2011

Bristol To Support Grants For Studies On Drug Resistance

June 26, 1987

Deflecting Earmarks, NCI Advisors Lay Out Research Opportunities In Breast, Prostate

February 26, 1999

Lame-Duck Session Required To Complete HHS Funding Bill; Nobel Laureates For Gore.

November 10, 2000

NCI-Approved CTEP Trials For the Month of December

December 28, 2012

Obama Picks Hamburg for FDA Commissioner

March 20, 2009